

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT – INCLUSION OF TREPROSTINIL INJECTION, TEGLUTIK AND TRITTICO IN THE NATIONAL REIMBURSEMENT DRUG LIST

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**” or “**Lee’s Pharm**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

The Board is pleased to announce that the Group’s commercialised products, namely Treprostinil Injection, Teglutik® and Trittico® have been included for the first time into the updated National Reimbursement Drug List (the “**NRDL**”) issued by the China National Healthcare Security Administration on 18 January 2023 and will be officially implemented from 1 March 2023.

Together with the other 6 products in the list, a total of 9 products of the Group have been included in the updated NRDL.

Among 111 products included for the first time in this updated NRDL, 7 of which are from rare disease area and the Group’s Treprostinil Injecton and Teglutik® have taken up 2 places thereof. Together with Trittico®, the Group firmly believed that the newly inclusion of these specialty drugs into the updated NRDL will help the Group to further enhance the affordability and accessibility thereof among patients in rare disease and mental health areas.

ABOUT TREPROSTINIL INJECTION

Treprostinil Injection is a generic product developed and manufactured by Zhaoke Pharmaceutical (Hefei) Company Limited (“**ZKHF**”), a wholly-owned subsidiary of the Company, and has been granted drug registration approval by National Medical Products Administration (“**NMPA**”) of the People’s Republic of China in March 2020 (Specification 20ml: 20mg) and March 2022 (Specification 20ml: 50mg), respectively.

* For identification purpose only

Treprostinil Injection is a subcutaneously or intravenously administered prostacyclin analogue for the treatment of pulmonary arterial hypertension (“PAH”) in patients (PAH; WHO Group 1) to diminish symptoms associated with exercise and improve exercise capacity. It is indicated for severe PAH patients with New York Heart Association Functional (“NYHA”) classification II, III, or IV. Studies establishing effectiveness included patients with NYHA Functional Class II–IV symptoms and etiologies of idiopathic or heritable PAH, PAH associated with congenital systemic-to-pulmonary shunts, or PAH associated with connective tissue diseases.

ABOUT Teglutik®

Teglutik® is licensed-in from Italfarmaco S.A. and has been granted drug registration approval by NMPA of the People’s Republic of China in May 2022.

Teglutik® (Riluzole) oral suspension is a neuroprotective agent indicated for the treatment of Amyotrophic Lateral Sclerosis (“ALS”). ALS is a fatal, adult-onset neurodegenerative disorder, which affects upper and/or lower motor neurons and is associated with degeneration of cortical and spinal motor neurons. Signs and symptoms of neurodegeneration are represented by progressive weakness of the bulbar, limb, thoracic and abdominal muscles. Cognitive dysfunction and dementia occur in 20–50% and 5–15% of cases, respectively. The disorder is one of the most common forms of Motor Neurone Disease (“MND”), representing more than 85% of all MND cases.

ABOUT Trittico®

Trittico® (trazodone hydrochloride tablets) is licensed-in from Angelini Pharma and has been granted drug registration approval by NMPA of the People’s Republic of China in December 2020.

Trazodone, a potent postsynaptic serotonin 5-HT_{2A} receptor antagonist and a moderate inhibitor of serotonin reuptake, is the original member of the SARIs (serotonin-2 antagonist/reuptake inhibitors) group of antidepressants. Trittico® is a prolonged-release formulation with better patient compliance than any immediate release formulation of the molecule.

By order of the Board
Lee’s Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 19 January 2023

As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive Directors of the Company, Dr. Li Xiaoyi and Mr. James Charles Gale are non-executive Directors of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive Directors of the Company.